Radiotheranostics Market Future Scope and Latest Trends Analysis Report

Radiotheranostics Market worth $3.86 Bn by 2030 - Exclusive Report by InsightAce Analytic

InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on "Global Radiotheranostics Market By radioisotope (technetium-99, gallium-68, iodine-131, iodine-123, 18F, y-90, lutetium (lu) 177, copper (Cu) 67, copper (Cu) 64, others), Source (Nuclear Reactors, Cyclotrons), Approach (Targeted Therapeutic (Rx), Companion Diagnostic (DX)), Applications (Oncology (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma, Lymphoma, Others) And Non-Oncology (Joint Infections, Arthritis, Bone Pain, Others)) And End Users (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies And Others))- By Trends, Industry Competition Analysis, Revenue and Forecast Till 2030"

According to the latest research by InsightAce Analytic, the global radiotheranostics market size valued at US$ 1.55 billion in 2024 and it is expected to reach US$ 3.86 billion in 2030, recording a promising CAGR of 10.90% during the period of 2024-2031.

The prominent players involved in the Radiotheranostics market are TransCode Therapeutics, Inc., Curium SAS, Affibody Medical AB, GE Healthcare Inc., MIM Software Inc., Bayer AG, Radiopharm Theranostics, Lantheus Medical, Imaging, Inc., Novartis AG, Spectrum Pharmaceuticals, Inc., Ipsen S.A., Actinium Pharmaceuticals, Inc. (ATNM), Nordic Nanovector ASA, Y-mAbs Therapeutics, Inc., Sofie Biosciences, Inc., Terumo Corporation, Sirtex Medical Limited, Boston Scientific Corporation, Nihon Medi-Physics, ITM Isotopen Technologien München AG, Advanced Accelerator Applications, Telix Pharmaceuticals, TRIMT GmbH, Theragnostics Ltd., NuView Life Sciences, Jubilant Pharma Limited, and Clarity Pharmaceuticals.

Get a free sample copy of the report : https://www.insightaceanalytic.com/request-sample/1499

The growing use of radio theranostics in cancer detection and treatment drives the industry. The market is expanding favourably due to discoveries and advancements in radiotheranostics. In radiotheranostics, for instance, notable results have been obtained for neuroendocrine tumours and prostate cancer. Improved patient outcomes are also a result of radiothermodynamics' increased treatment efficacy and capacity to handle challenging and urgent medical circumstances.

Following regulatory approval, the market expects increased usage of radiotheranostics pairs for cancer treatments. However, the market's growth is impeded by high R&D expenses, inadequate infrastructure, radiopharmaceuticals' short half-lives, expensive equipment, and a lack of awareness in developing countries. Hospital budget cuts, especially during the pandemic, inadequate infrastructure in low- and middle-income nations, an unfavourable reimbursement scenario, and the spread of technology in developing countries are expected to present additional market issues.

Radiotheranostics is a subset of theranostics that uses radioactive materials for therapeutic and diagnostic imaging. Radiotheranostic medicine adheres to the highest standards of personalized medicine by using paired therapeutic/diagnostic radionuclide probes for the targeted and selective diagnosis and treatment of particular (often cancerous) cells, with each probe tailored to the patient's unique underlying condition. Prostate cancer, neuroendocrine tumours, and other illnesses have all seen notable and encouraging advancements in radiotheranostics recently. Soon, several radiotheranostic combinations are anticipated to receive regulatory approval. Radiotheranostics makes better treatment outcomes and the ability to manage complex and life-threatening medical illnesses possible.

Therefore, to stay up with the latest advancements in radiotheranostics, research and development expenditures are continuing to support the market progress. The market for radiotheranostics in North America is anticipated to grow significantly. Neuroendocrine tumours (NETs) are highly prevalent in North America, which drives the market. Significant end users' extensive uptake of flow cytometry technology has created the North American market.

Furthermore, the Asia Pacific market for radiothermotheranostics was significantly dominated. Because of the growth in federal campaigns to raise awareness, the rise in medical tourism, the expansion of research activities in the area, the presence of major industry players, the availability of large, untapped markets, a sizable population pool, the availability of well-established infrastructure, the rise in cases of cardiovascular disease, and the growing demand in the area for high-quality healthcare programs.

Curious about this latest version of report? Obtain Report Details @ https://www.insightaceanalytic.com/enquiry-before-buying/1499

Key Industry Developments:
• In Oct 2022, Clarity Pharmaceuticals announced that the first patient in its Phase I/II theranostic trial, which is testing 64Cu/67Cu SAR-bisPSMA theranostic products in people with metastatic, castrate-resistant prostate cancer, has been given a dose (mCRPC). The promising preclinical and clinical results so far support Clarity's investigation of the optimised SAR-bisPSMA product in additional oncology indications where the theranostic approach may be useful.

• In May 2022, TransCode Therapeutics, Inc. announced the execution of an option agreement under which TransCode will have the right to negotiate an exclusive, worldwide, royalty-bearing licence for a radiotheranostic technology disclosed in patent application PCT/US2021/057912 entitled THERAPEUTIC, RADIOLABLED NANOPARTICLES AND METHODS OF USE THEREOF.

• In March 2022, Novartis announced that the US Food and Drug Administration (FDA) had approved PluvictoTM (lutetium Lu 177 vipivotide tetraxetan), which used to be called 177Lu-PSMA-617, to treat adults with a type of advanced cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body (metastatic). These patients have already been provided other treatments for cancer (androgen receptor pathway inhibition and taxane-based chemotherapy).

• In June 2021, At the Society of Nuclear Medicine and Molecular Imaging's (SNMMI) 2021 summer conference, GE Healthcare demonstrated innovative molecular imaging technologies and solutions and new prospects to improve access to radioactive tracers and other pharmaceutical imaging agents. This increased access to the most advanced and innovative precision diagnostics and radiopharmaceuticals, particularly in light of recent FDA approvals of critical new therapies, can provide clinicians with unique opportunities to make personalised care decisions and treatment response assessments that may help improve patient outcomes.
Market Segments

Global Radiotheranostics Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Radioisotope
• Technetium-99
• Gallium-68
• Iodine-131
• Iodine-123
• 18F
• Y-90
• Lutetium (Lu) 177
• Copper (Cu) 67
• Copper (Cu) 64
• Others

Global Radiotheranostics Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Source
• Nuclear Reactors
• Cyclotrons

Global Radiotheranostics Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Approach
• Targeted Therapeutic (Rx)
• Companion Diagnostic (DX)

Global Radiotheranostics Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Application
• Oncology
o Thyroid Cancer
o Neuroendocrine Cancer
o Hepatocellular Carcinoma
o Multiple Myeloma
o Lymphoma
o Others
• Non-Oncology
o Joint Infections
o Arthritis
o Bone Pain
o Others

Global Radiotheranostics Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on End User
• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Others

Global Radiotheranostics Market Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America Radiotheranostics market revenue (US$ Million) by Country, 2022 to 2030
• U.S.
• Canada

Europe Radiotheranostics market revenue (US$ Million) by Country, 2022 to 2030
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific Radiotheranostics market revenue (US$ Million) by Country, 2022 to 2030
• India
• China
• Japan
• South Korea
• Australia & New Zealand

Latin America Radiotheranostics market revenue (US$ Million) by Country, 2022 to 2030
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa Radiotheranostics market revenue (US$ Million) by Country, 2022 to 2030
• GCC Countries
• South Africa
• Rest of Middle East & Africa

For More Information @ https://www.insightaceanalytic.com/customisation/1499

Why should buy this report:
 To receive a comprehensive analysis of the prospects for global Radiotheranostics market
 To receive industry overview and future trends of global Radiotheranostics market
 To analyse the Radiotheranostics market drivers and challenges
 To get information on Radiotheranostics market size value (US$ Mn) forecast till 2030
 Major Investments, Mergers & Acquisition in global Radiotheranostics market industry
Other Related Reports Published by InsightAce Analytic:
Global Radioligand Therapy Market
Global Radiation Therapy Quality Assurance Phantoms Market
Radiation Dose Management Market
Global Interventional Radiology Products Market

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 551 226 6109
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.